Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02057133
Title A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Highlands Oncology Group Fayetteville Arkansas 72703 United States Details
University of California - San Diego La Jolla California 92037-0845 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
Mayo Clinic Rochester Minnesota 55905-0002 United States Details
Columbia University College of Phys & Surgeons New York New York 10032 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
University of North Carolina at Chapel Hill Chapel Hill North Carolina 27514 United States Details
Peggy and Charles Stephenson Oklahoma Cancer Center Oklahoma City Ohio 73104 United States Details
Providence Cancer Center Oncology Hematology Care Portland Oregon 97213 United States Details
Univ of Pittsburgh Cancer Inst. (UPCI) Pittsburgh Pennsylvania 15213 United States Details
Sarah Cannon Cancer Center Nashville Tennessee 37203 United States Details
Tennessee Oncology PLLC Nashville Tennessee 37203 United States Details
Vanderbilt University Medical Center Nashville Tennessee 37232-6307 United States Details
Texas Oncology-Baylor Charles A. Sammons Cancer Center Dallas Texas 75246 United States Details
South Texas Accelerated Research Therapeutics, LLC San Antonio Texas 78229-3307 United States Details
US Oncology The Woodlands Texas 77380 United States Details
*Shaded cells indicate that there was no data available from for the field